CN104583240B - 结合有细胞质转导肽及聚乙二醇的干扰素α融合蛋白 - Google Patents

结合有细胞质转导肽及聚乙二醇的干扰素α融合蛋白 Download PDF

Info

Publication number
CN104583240B
CN104583240B CN201380043015.XA CN201380043015A CN104583240B CN 104583240 B CN104583240 B CN 104583240B CN 201380043015 A CN201380043015 A CN 201380043015A CN 104583240 B CN104583240 B CN 104583240B
Authority
CN
China
Prior art keywords
ifnα
fusion protein
interferon
ctp
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380043015.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104583240A (zh
Inventor
裴容洙
洪承镐
金荣训
韩承洙
金真
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JW CREAGENE Inc
Original Assignee
JW CREAGENE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JW CREAGENE Inc filed Critical JW CREAGENE Inc
Publication of CN104583240A publication Critical patent/CN104583240A/zh
Application granted granted Critical
Publication of CN104583240B publication Critical patent/CN104583240B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380043015.XA 2012-08-13 2013-08-07 结合有细胞质转导肽及聚乙二醇的干扰素α融合蛋白 Expired - Fee Related CN104583240B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0088610 2012-08-13
KR20120088610 2012-08-13
PCT/KR2013/007136 WO2014027789A1 (ko) 2012-08-13 2013-08-07 세포질 잔류성 세포막 투과 펩타이드 및 폴리에틸렌글리콜이 결합된 인터페론 알파 융합 단백질

Publications (2)

Publication Number Publication Date
CN104583240A CN104583240A (zh) 2015-04-29
CN104583240B true CN104583240B (zh) 2017-11-28

Family

ID=50685640

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380043015.XA Expired - Fee Related CN104583240B (zh) 2012-08-13 2013-08-07 结合有细胞质转导肽及聚乙二醇的干扰素α融合蛋白

Country Status (6)

Country Link
US (1) US9682152B2 (enExample)
JP (1) JP6010227B2 (enExample)
KR (1) KR102012025B1 (enExample)
CN (1) CN104583240B (enExample)
IN (1) IN2015DN01371A (enExample)
WO (1) WO2014027789A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987381B (zh) * 2015-06-11 2018-11-27 吉林大学 重组正电荷多肽干扰素及在抗肿瘤和抗病毒治疗中的应用
WO2021062181A1 (en) * 2019-09-26 2021-04-01 Orionis Biosciences, Inc. Conjugated chimeric proteins
KR20230099956A (ko) * 2021-12-28 2023-07-05 제이더블유크레아젠 주식회사 면역세포에 항원을 전달하기 위한 폴리펩타이드
CN114853911B (zh) * 2022-05-23 2024-06-28 复旦大学 三叶因子2/干扰素α2融合蛋白及其防治病毒感染性疾病的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100108028A (ko) * 2009-03-27 2010-10-06 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 ＩＦＮ-α 융합 단백질
CN101942026A (zh) * 2010-10-14 2011-01-12 成都正能生物技术有限责任公司 长效干扰素融合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE441661T1 (de) * 2002-03-29 2009-09-15 Creagene Inc Zytoplasmatische transduktionspeptide und deren verwendungen
RU2008109649A (ru) * 2005-08-15 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В
JP2010529859A (ja) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EP2412730B1 (en) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100108028A (ko) * 2009-03-27 2010-10-06 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 ＩＦＮ-α 융합 단백질
CN101942026A (zh) * 2010-10-14 2011-01-12 成都正能生物技术有限责任公司 长效干扰素融合蛋白及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
长效干扰素研究进展;田硕等;《中国生物工程杂志》;20100515;第30卷(第5期);122-127 *

Also Published As

Publication number Publication date
CN104583240A (zh) 2015-04-29
IN2015DN01371A (enExample) 2015-07-03
KR102012025B1 (ko) 2019-08-19
JP6010227B2 (ja) 2016-10-19
JP2015526084A (ja) 2015-09-10
US20150202312A1 (en) 2015-07-23
KR20150063375A (ko) 2015-06-09
US9682152B2 (en) 2017-06-20
WO2014027789A1 (ko) 2014-02-20

Similar Documents

Publication Publication Date Title
JP6722227B2 (ja) ヘプシジン類似体及びその使用
CA2829693C (en) Pegylated apelin and uses thereof
CA2557782A1 (en) Glycol linked fgf-21 compounds
WO2011020319A1 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
JP2002506792A (ja) Ｎ末端修飾ｇｌｐ−１誘導体
US20140228285A1 (en) Multi-Substituted Insulins
CN104583240B (zh) 结合有细胞质转导肽及聚乙二醇的干扰素α融合蛋白
CN103237808A (zh) 抗癌融合蛋白
US20120128629A1 (en) Method of labelling interferons with peg
JP2003500456A (ja) 角質細胞増殖因子−２製剤
JP2000511762A (ja) ケラチノサイト増殖因子アナログ
EP0596969A1 (en) Igf-ii analogues
US10308917B2 (en) Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof
CN120230181A (zh) 一种具有抑制肿瘤细胞增殖功能的多肽pka15及其应用
US8623348B2 (en) Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
JPH10330284A (ja) 肝細胞保護剤
JPH10330283A (ja) 消化管組織再生賦活剤
US20230174606A1 (en) Interferon alpha 2 variants and uses thereof
KR101183826B1 (ko) 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 ＩＦＮ-α 융합 단백질
JPH05178756A (ja) 肝疾患の予防・治療薬
BR112012014017B1 (pt) Uso de conjugados proteína-polímero
HK1254031A1 (en) Vegf antagonist compositions and uses thereof
JP2004284977A (ja) ヒト生理活性物質とヒト蛋白質合成阻害物質との挿入融合体
JPH05186367A (ja) 高脂血症治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171128

CF01 Termination of patent right due to non-payment of annual fee